There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), 10x Genomics (TXG – Research Report) and Altimmune (ALT – Research Report) with bullish sentiments.
AbbVie (ABBV)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on AbbVie on January 19 and set a price target of $180.00. The company’s shares closed last Monday at $165.12, close to its 52-week high of $166.20.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $173.69 average price target, representing a 5.6% upside. In a report issued on January 8, TD Cowen also maintained a Buy rating on the stock with a price target.
See Insiders’ Hot Stocks on TipRanks >>
10x Genomics (TXG)
In a report issued on January 19, Daniel Arias from Stifel Nicolaus maintained a Buy rating on 10x Genomics, with a price target of $68.00. The company’s shares closed last Monday at $43.26.
According to TipRanks.com, Arias is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 10x Genomics with a $57.82 average price target, representing a 36.0% upside. In a report issued on January 8, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.
Altimmune (ALT)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune on January 19 and set a price target of $15.00. The company’s shares closed last Monday at $9.77.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $21.83, implying a 137.8% upside from current levels. In a report issued on January 11, Jefferies also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABBV:
- SHARx files defamation lawsuit against AbbVie
- AbbVie launches Produodopa in European Union
- AbbVie reports ‘positive’ results from Phase 2 trial of lutikizumab
- AbbVie and Umoja Biopharma partnering to develop in-situ CAR-T cell therapies
- CVS Caremark accelerates biosimilars adoption through formulary changes
